Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check5 days agoChange DetectedA site-wide notice about a lapse in government funding and potential data delays was added. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check12 days agoChange DetectedAdded a glossary display, introduced a new 'Last Update Submitted that Met QC Criteria' label, and updated the capitalization to 'No FEAR Act Data'. Updated the revision reference from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision: v3.3.4 update shows no substantive changes to the study details, eligibility criteria, locations, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedDistrict of Columbia was added to the Locations section. The District of Columbia Locations entry and HHS Vulnerability Disclosure were removed, and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check76 days agoChange DetectedAdded a note that publications shown are automatically filled from PubMed and may not be about the study. Updated the revision tag from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check83 days agoChange DetectedRemoved the warning banner about potential data delays due to a lapse in government funding. The banner previously informed users that information on the site may not be up to date and that the agency may not respond until appropriations are enacted.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.